Cladribine (2-chlorodeoxyadenosine)

Same author

1342C mutation in Gaucher's disease.

Lancet (London, England)·1995

Same author

Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families.

American journal of hematology·1995

Same author

Gaucher disease.

Medicine·1995

Same author

Treatment regimens in Gaucher's disease.

Lancet (London, England)·1995

Same author

Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

The Journal of clinical investigation·1995

Same author

Erythrocyte fragility and chronic intermittent pigmenturia in a dog.

Journal of the American Veterinary Medical Association·1995

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026

Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026

Related Experiment Videos

Cladribine (2-chlorodeoxyadenosine)

Related Concept Videos

1342C mutation in Gaucher's disease.

Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families.

Gaucher disease.

Treatment regimens in Gaucher's disease.

Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

Erythrocyte fragility and chronic intermittent pigmenturia in a dog.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Related Experiment Videos

Cladribine (2-chlorodeoxyadenosine)

Related Concept Videos

Related Articles

1342C mutation in Gaucher's disease.

Triosephosphate isomerase deficiency: repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families.

Gaucher disease.

Treatment regimens in Gaucher's disease.

Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

Erythrocyte fragility and chronic intermittent pigmenturia in a dog.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.